[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.191.0. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 544
Citations 0
Original Investigation
December 5, 2019

Association of Postfungal Keratitis Corneal Scar Features With Visual Acuity

Author Affiliations
  • 1Department of Ophthalmology, University of Washington, Seattle
  • 2Department of Cornea and Refractive Surgery, Aravind Eye Care System, Madurai, India
  • 3Department of Ophthalmology, University of California, San Francisco, San Francisco
  • 4Francis I. Proctor Foundation, University of California, San Francisco, San Francisco
  • 5Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco
  • 6Institute for Global Health, University of California, San Francisco, San Francisco
JAMA Ophthalmol. 2020;138(2):113-118. doi:10.1001/jamaophthalmol.2019.4852
Key Points

Question  Which features of a postfungal keratitis corneal scar contribute most to vision loss?

Findings  In this ancillary cross-sectional study of a subset of 71 patients treated for fungal keratitis in the Mycotic Ulcer Treatment Trial I, irregular astigmatism and scar density were the features most strongly associated with vision loss. The thinnest point of the cornea was the metric that best discriminated between the natamycin- and voriconazole-treated ulcers.

Meaning  The findings of this study suggest that irregular astigmatism, scar density, and the thinnest point of the cornea may be meaningful cornea-specific metrics that could be used as outcomes in clinical research.

Abstract

Importance  Corneal opacity is a leading cause of visual impairment worldwide; however, the specific features of corneal scars, which decrease visual acuity, have not been well characterized.

Objective  To investigate which features of a postfungal keratitis corneal scar contribute to decreased visual acuity after an episode of infectious keratitis and evaluate whether any corneal features may be used as outcomes for clinical trials.

Design, Setting, and Participants  In this ancillary, prospective cross-sectional study, a subset of study participants treated for fungal keratitis (n = 71) as part of the Mycotic Ulcer Treatment Trial I (MUTT I) underwent best spectacle-corrected visual acuity (BSCVA) and best contact lens–corrected visual acuity examination, Scheimpflug imaging, and anterior segment optical coherence tomography at a referral hospital in India approximately 2 years after enrollment. Data were collected from December 3, 2012, to December 19, 2012, and analyses were performed from December 2, 2013, to October 2, 2019.

Main Outcomes and Measures  Linear regression models were used to evaluate the importance of various corneal features for BSCVA and to assess whether these features could be used to differentiate the 2 treatment arms of the MUTT I trial.

Results  Seventy-one patients (42 men [59.1%]; median age, 48 [range, 39-60] years) were examined at a median (IQR) time of 1.8 (1.4-2.2) years after enrollment. The mean (SD) logMAR BSCVA was 0.17 (0.19) (Snellen equivalent, 20/32). In multivariable linear regression models, BSCVA was most associated with irregular astigmatism (1.0 line of worse BSCVA per 1-line difference between BSCVA and contact lens visual acuity; 95% CI, 0.6-1.4) and corneal scar density (1.5 lines of worse vision per 10-unit increase in the mean central corneal density; 95% CI, 0.8-2.3). The thinnest point of the cornea was the metric that best discriminated between the natamycin- and voriconazole-treated ulcers in MUTT I, with 29.3 μm (95% CI, 7.1-51.6 μm) less thinning in natamycin-treated eyes.

Conclusions and Relevance  Both irregular astigmatism and corneal scar density may be important risk factors for BSCVA in a population with relatively mild, healed fungal corneal ulcers. The thinnest point of the corneal scar may be a cornea-specific outcome that could be used to evaluate treatments for corneal ulcers.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×